$3.77
3.86% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US41015N1063
Symbol
NVNO

Hancock Jaffe Laboratories, Inc. Stock price

$3.77
+1.35 55.79% 1M
+0.40 11.87% 6M
+0.75 24.83% YTD
-1.23 24.60% 1Y
-0.39 9.38% 3Y
-5.97 61.28% 5Y
-127.23 97.12% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.14 3.86%
ISIN
US41015N1063
Symbol
NVNO
Sector

Key metrics

Market capitalization $66.11m
Enterprise Value $28.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.73
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-23.28m
Free Cash Flow (TTM) Free Cash Flow $-17.33m
Cash position $38.94m
EPS (TTM) EPS $-1.24
Short interest 2.26%
Show more

Is Hancock Jaffe Laboratories, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Hancock Jaffe Laboratories, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Hancock Jaffe Laboratories, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Hancock Jaffe Laboratories, Inc.:

Buy
100%

Financial data from Hancock Jaffe Laboratories, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.51 0.51
7% 7%
-
-0.51 -0.51
7% 7%
-
- Selling and Administrative Expenses 11 11
7% 7%
-
- Research and Development Expense 12 12
10% 10%
-
-23 -23
3% 3%
-
- Depreciation and Amortization 0.51 0.51
7% 7%
-
EBIT (Operating Income) EBIT -23 -23
3% 3%
-
Net Profit -21 -21
4% 4%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hancock Jaffe Laboratories, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hancock Jaffe Laboratories, Inc. Stock News

Neutral
Accesswire
one day ago
IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, announced the appointment of Jennifer Bright as Chief Financial Officer, effective today, May 19, 2025. Ms. Bright brings more than 25 years of financial and strategic leadership experience built a...
Neutral
Accesswire
8 days ago
Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and maintaining clinical benefits Company has submitted PMA application for the VenoValve to the U.S. Food and Drug Administration (FDA) with a decision anticipated in the second half of 202...
Neutral
Accesswire
20 days ago
Cash Burn of $4.0 million in Q1 remains in line with projected quarterly range Cash and investments on hand are sufficient to fund operations beyond the anticipated FDA decision of VenoValve and the initiation of the enVVe pivotal trial FDA decision on PMA application for the VenoValve expected in the second half of 2025 On track for enVVe IDE application submission in Q3 of 2025, pending GLP s...
More Hancock Jaffe Laboratories, Inc. News

Company Profile

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include The Bioprosthetic Heart Valve, The CoreoGraft, and The Venous Valve. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

Head office United States
CEO Robert Berman
Employees 37
Founded 1999
Website www.envveno.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today